image description

RuiHui (Rachel) Yu


RuiHui (Rachel) Yu

New York +1-212-558-4000+1-212-558-4000 +1-212-558-3588+1-212-558-3588
[email protected]

RuiHui (Rachel) Yu is a partner in Sullivan & Cromwell’s General Practice Group. Ms. Yu’s practice concentrates on transactional work involving complex technology, intellectual property, and cybersecurity issues, including mergers and acquisitions, divestitures, licenses and transfers of intellectual property, joint ventures, research and development agreements, collaborations, data agreements, financings, settlements and strategic advice. She counsels clients in a wide range of industries, including healthcare and life sciences, software and other technology, consumer and retail, financial services, and media and telecommunications. Ms. Yu was named by The Best Lawyers in America: Ones to Watch for Intellectual Property Law (2022).

A thought-leader in the field, Ms. Yu is a Lecturer in Law at Columbia Law School, where she teaches a course on IP transactions. She also regularly speaks on topics involving intellectual property and trademark law and artificial intelligence.

Ms. Yu is also committed to pro bono. For many years, she has co-led the Legal Aid Society’s Associates’ Campaign in its annual fundraising efforts at the firm. Most recently, she has also represented clients in transgender name changes, in an uncontested divorce case and through the Clemency Project.


Healthcare & Life Sciences
  • Abiomed in its $18 billion acquisition by Johnson & Johnson 
  • A consortium led by Ally Bridge Group Capital Partners, in its acquisition of WuXi PharmaTech for approximately $3.3 billion – one of the largest going-private transactions, as well as one of the largest leveraged buyouts for a Chinese business
  • Amgen in its $28.3 billion pending acquisition of Horizon Therapeutics and approximately $1.9 billion acquisition of Five Prime Therapeutics
  • Anika Therapeutics in its acquisitions of Arthrosurface for up to $100 million and Parcus Medical for up to $95 million
  • Bausch Health (formerly Valeant Pharmaceuticals) in its collaboration agreement with AstraZeneca, under which Valeant was granted an exclusive license to develop and commercialize brodalumab, acquisition of Commonwealth Laboratories’ business in the United States and Canada and acquisition of Unilens Vision for approximately $28 million
  • Bayer AG in its $66 billion acquisition of Monsanto Company and approximately $9 billion divestiture in assets to BASF, and the $7.6 billion sale of its animal health business to Elanco Animal Health
  • Biohaven Pharmaceuticals in Pfizer's $11.6 billion acquisition of all outstanding shares of Biohaven not already owned by Pfizer, acquisition of Channel Biosciences, a subsidiary of Knopp Biosciences, and its Kv7 channel targeting platform, $1.24 billion strategic commercialization arrangement with Pfizer for rimegepant, commercialized as Nurtec® ODT in the U.S., in markets outside of the United States upon approval, and sale of tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000) or BHV-3500 and certain derivative compounds thereof to Royalty Pharma for $100 million
  • Novartis in its $9.7 billion acquisition of The Medicines Company
  • Oaktree Capital Management in its debt capitalization transaction with Oxford Biomedica
  • Royal Phillips in its acquisition of the Healthcare Information Systems business of Carestream Health and $2 billion acquisition of The Spectranetics Corporation
  • Stemcentrx in its $9.8 billion acquisition by AbbVie 
  • Sumitovant Biopharma and Sumitomo Pharma in their $2.9 billion pending acquisition of Myovant Sciences 
  • Sumitovant Biopharma in the collaboration of its subsidiary Myovant Sciences with Pfizer to develop and commercialize Sumitovant’s ORGOVYXTM (relugolix)
  • Terumo Corporation in its $1.12 billion acquisition of certain products from Abbott Laboratories and St. Jude Medical
  • UnitedHealth Group in its divestiture of ClaimsXten, the claims editing business of Change Healthcare, to an affiliate of investment funds of TPG Capital for $2.2 billion
  • Verily Life Sciences, an Alphabet company, in connection with Temasek’s $800 million investment in Verily in exchange for a minority stake in the company

  • Ally Financial in its $2.65 billion proposed acquisition of CardWorks, later terminated
  • AST SpaceMobile in its pending common stock purchase agreement with B. Riley Principal Capital, pursuant to which AST SpaceMobile may sell and issue up to $75 million of its Class A Common Stock to B. Riley
  • Fifteen major universities in a joint patent licensing program called University Technology Licensing Program
  • Harris Corporation in its $35 billion merger of equals with L3 Technologies and its $350 million sale of its Night Vision business to Elbit Systems of America
  • The underwriters of Mobileye Global Inc. in its $861 million SEC-registered IPO and Nasdaq Global Select Market listing 
  • Unisys Corp. in its $1.2 billion sale of its U.S. federal business to Science Applications International Corp.
  • Watlow Electric Manufacturing Company in its sale to Tinicum L.P.
  • Ziff Davis in its asset purchase agreement for Gawker Media Group’s media properties Gizmodo, Lifehacker, Kotaku, Jalopnik, Deadspin, Jezebel and Gawker

Retail and Consumer
  • Anheuser-Busch InBev in various strategic transactions, including its strategic relationship with a consortium of investors led by Apollo Global Management, which acquired a $3 billion minority stake in AB InBev’s U.S.-based metal container plants, divestiture of Craft Brew Alliance’s Kona Brewing Operations in Hawaii to PV Brewing Partners, and its acquisition of ready-to-drink, cider and craft beer brands for the Canadian and other markets from the Mark Anthony Group of companies
  • Booking Holdings in its $1.2 billion acquisition of Getaroom from Court Square Capital Partners
  • Grupo Carrefour Brasil in its approximately $1.2 billion acquisition of Grupo BIG Brasil SA from Advent International and Walmart
  • Haleon Group in its demerger from the GSK Group, making Haleon the world’s biggest stand-alone consumer health company
  • Panera Bread Company in its $7.5 billion acquisition by JAB
  • Sotheby’s in its acquisition of Viyet, an online marketplace for interior design
  • TheNotCompany in its joint venture with The Kraft Heinz Company
  • Tiffany & Co. in its acquisition by LVMH Moët Hennessy for approximately $16 billion

Other Representations
  • DS Smith in its $585 million sale of the Plastics division to Olympus Partners; and Insight Enterprises in its $581 million acquisition of PCM
  • Fletcher Building in its $840 million sale of the Formica Group to Broadview Holding
  • TS Innovation Acquisitions Corp., a SPAC formed by Tishman Speyer Properties, in its $1.56 billion merger with Latch and $190 million PIPE in connection with the merger​